Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 24, 2015 - Issue 12
Submit an article Journal homepage
546
Views
13
CrossRef citations to date
0
Altmetric
Drug Evaluation

Docetaxel for the treatment of bladder cancer

Costantine AlbanyDepartment of Medicine, Section of Hematology-Oncology, Indiana University Simon Cancer Center, Indianapolis, IN46202, USA
&
Guru SonpavdeDepartment of Medicine, Section of Hematology-Oncology, Veterans Affairs Medical Center, Birmingham, AL, USA;Department of Medicine, Section of Hematology-Oncology, University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham, AL35294, USACorrespondence[email protected]
Pages 1657-1664 | Published online: 04 Nov 2015

Bibliography

  • • of interest
  • •• of considerable interest
  • Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234–241.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
  • von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–4608.
  • Sonpavde G, Sternberg CN, Rosenberg JE, et al. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010;11:861–870.
  • Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454–4461.
  • Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30:1107–1113.
  • Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29:2432–2438.
  • Sonpavde G, Watson D, Tourtellott M, et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer. 2012;10:1–5.
  • De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191–199.
  • Sonpavde G, Galsky MD, Latini D, et al. Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. Clin Genitourin Cancer. 2014;12:71–73.
  • von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–3077.
  • Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564–2569.
  • Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638–2646.
  • McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15:1853–1857.

•• This is a phase II trial enrolling 30 patients that administered single agent docetaxel 100 mg/m2 every 21 days as second-line therapy for metastatic UC after progression on one prior cisplatin-based chemotherapy regimen and showed a response rate of 13.3% and a median survival of 9 months.

  • Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002;20:937–940.
  • Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997;15:589–593.
  • Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24:3451–3457.
  • Joly F, Houede N, Noal S, et al. Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer. 2009;7:E28–E33.
  • Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93:2325–2327.
  • Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol. 1994;5:495–505.
  • Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980;77:1561–1565.
  • Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991;83:288–291.
  • Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther. 1991;52:35–84.
  • Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci. 1992;13:134–136.
  • Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665–667.
  • Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry. 1993;32:2747–2755.
  • Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 1994;344:1267–1272.
  • Bruno R, Riva A, Hille D, et al. Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials. Am J Health Syst Pharm. 1997;54:S16–S19.
  • Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol. 1997;15:3149–3155.
  • Schrijvers D, Pronk L, Highley M, et al. Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. Am J Clin Oncol. 2000;23:358–363.
  • Rangel C, Niell H, Miller A, et al. Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol. 1994;33:460–464.
  • de Wit R, Kruit WH, Stoter G, et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer. 1998;78:1342–1345.
  • Sengelov L, Kamby C, Lund B, et al. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol. 1998;16:3392–3397.
  • Artz A, Stadler WM, Vogelzang NJ, et al. A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. Am J Clin Oncol. 2005;28:109–113.
  • Ardavanis A, Tryfonopoulos D, Alexopoulos A, et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer. 2005;92:645–650.
  • Gitlitz BJ, Baker C, Chapman Y, et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer. 2003;98:1863–1869.
  • Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:220–228.
  • Chen AC, Hovey E, Shelton G, et al. Phase I/II study of docetaxel (D), gemcitabine (G), Carboplatin (C) in poor prognosis and previously treated patients (pts) with urothelial carcinoma (UTC). J Clin Oncol (Meeting Abstracts). 2004;22(14_suppl):458.
  • Takahashi S, Suzuki M, Kume H, et al. Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. Jpn J Clin Oncol. 2005;35:79–83.
  • Krege S, Rembrink V, Borgermann C, et al. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol. 2001;165:67–71.
  • Sonpavde G, Pond GR, Mullane S, et al. Incomplete cross-resistance between taxanes for advanced urothelial carcinoma: implications for clinical practice and trial design. Clin Genitourin Cancer. 2015;13:250–256.
  • Clark PE, Agarwal N, Biagioli MC, et al. Bladder cancer. J Natl Compr Canc Netw. 2013;11:446–475.
  • Pectasides D, Glotsos J, Bountouroglou N, et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol. 2002;13:243–250.
  • Milowsky MI, Nanus DM, Maluf FC, et al. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol. 2009;27:4062–4067.
  • Choueiri TK, Ross RW, Jacobus S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012;30:507–512.

• This is a randomized phase II trial that did not demonstrate improved outcomes by the combination of vendetanib with docetaxel,and revealed a dismal median PFS of 1.58 months and median OS of 7.03 months with docetaxel.

  • Petrylak DP, Tagawa ST, Kohli M, et al. Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma. J Clin Oncol. 2015;33(Suppl 7): abstr 295.

• This is a recently reported randomized phase II trial that revealed a significant extension of PFS with the combination of ramucirumab with docetaxel as salvage therapy for metastatic UC.

  • Bambury RM, Benjamin DJ, Chaim JL, et al. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. Oncologist. 2015;20:508–515.
  • Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–562.
  • Plimack ER, Gupta S, Bellmunt J, et al. A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced urothelial tract cancer. ESMO Congress; 2014 Sep 30; Madrid; abstract LBA23.
  • Pond GR, Agarwal N, Bellmunt J, et al. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014;113:E137–E143.
  • Sonpavde G, Pond GR, Choueiri TK, et al. Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. Eur Urol. 2015.
  • Sonpavde G, Pond GR, Rosenberg JE, et al. Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. J Urol. 2015.

• This is a recently reported improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. The uniform use of this classification in randomized trials will assist with trial design and data interpretation.

  • Ko YJ, Canil CM, Mukherjee SD, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol. 2013;14:769–776.
  • Quinn DI, Twardowski P, Wei YE, et al. Phase II study of eribulin in platinum-treated, tubulin naive advanced urothelial cancer (UC) – a California Cancer Consortium trial (NCI/CTEP 7435). ECCO conference; 2013 Sep; Amsterdam; abstract 2704.
  • Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–322.
  • Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;111:3110–3115.
  • Choi W, Porten S, Kim S, et al. Identification of distinct Basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152–165.
  • Rebouissou S, Bernard-Pierrot I, de Reynies A, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med. 2014;6:244ra91.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.